RE:RE:RE:RE:“Second mouse gets the cheese “Correction: the PancCan sponsored pancreatic cancer study with mFOLIRINOX is a cohort extention of the Phase 1/2 Goblet-1 study.
" ... a new Phase 1/2 cohort evaluating pelareorep in combination with modified FOLFIRINOX (mFOLFIRINOX) with and without atezolizumab (Tecentriq®) in patients with newly diagnosed metastatic pancreatic ductal adenocarcinoma (PDAC)..."
https://www.newswire.ca/news-releases/oncolytics-biotech-r-files-amendment-to-initiate-new-pancreatic-cancer-goblet-cohort-supported-by-pancan-881151697.html
Quite frankly I don't appreciate the kind of "Cheshire Cat" behavior that the prinicaples have been imposing on the shareholders of ONCY. I suggest that those principles begin to reverse this sort of "toying" behavior, since not all of us are as uninformed as they may think.